Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Specimen Handling 465Magnetic Resonance Spectroscopy 351pembrolizumab 297Biopsy 251Carboplatin 235Cisplatin 199Cyclophosphamide 191Paclitaxel 167Nivolumab 159Gemcitabine 154Radiotherapy 129Bevacizumab 128Dexamethasone 115fludarabine 103Pemetrexed 102Fluorouracil 96Radiation 94Doxorubicin 94atezolizumab 93Docetaxel 93durvalumab 92venetoclax 91Rituximab 89Oxaliplatin 89Leucovorin 82Capecitabine 79Prednisone 78Lenalidomide 72X-Rays 69Etoposide 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ivermectin × 30 days × Clear all
NCT05318469 2026-05-06

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Cedars-Sinai Medical Center

Phase 1/2 Recruiting
34 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡